Clinical trial
ALK Inhibitor in Metastatic Colorectal Cancer With ALK Mutation.
NCT03792568 is registered in ClinicalTrials.gov with Shanghai Changzheng Hospital as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- ALK Inhibitor in Metastatic Colorectal Cancer With ALK Mutation.
- Lead sponsor
- Shanghai Changzheng Hospital
- Phase
- Not applicable
- Overall status
- Unknown status
- Start date
- March 1, 2019
- Completion date
- March 1, 2021
- Enrollment
- 30 (estimated)
- Sites
- 3
Conditions
As the registry lists them; a condition with its own page is linked.
colorectal cancer